We’ve recently updated our electronic health record and other systems to better support your care. We appreciate your patience and understanding as we work through this change and look forward to caring for you!
For this sub-study, you will be assigned to treatment with talazoparib (BMN 673), a PARP inhibitor. The purpose of this sub-study is to find any good and bad effects of talazoparib (BMN 673). Talazoparib (BMN 673) may or may not shrink your cancer and it could also cause side effects.
